RxDoctor Payments Data

David Schaer, MD

Cardiovascular Disease · East Brunswick, NJNPI 1205892809

Payments from drug & device makers

$75,206in general payments, 2019–2025

Across 314 payments — averaging $239.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$69K
  • E.r. Squibb & Sons, L.L.C.$3K
  • Novartis$584
  • Abiomed$520
  • Abbott$333
  • Boston Scientific$212
  • plus $1K from 20 others

What the payments were for

  • Consulting fees$3000%
  • Speaking & faculty fees$67,57590%
  • Travel & lodging$2,2583%
  • Food & beverage$5,0737%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$75,206 in reported general payments places this provider in the 90th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$249,658
Medicare patients
799
Services billed
3,012

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban206$276,447
EliquisApixaban187$231,844
Repatha SureclickEvolocumab76$76,639
EntrestoSacubitril/Valsartan55$60,576
MultaqDronedarone Hcl33$57,632
Icosapent Ethyl48$28,704
Praluent PenAlirocumab27$25,496
VascepaIcosapent Ethyl23$22,254
LivaloPitavastatin Calcium31$18,473
Ezetimibe549$16,856
Ranolazine ErRanolazine119$14,351
Rosuvastatin Calcium764$12,112
Pitavastatin Calcium40$11,537
EdarbiAzilsartan Medoxomil17$11,499
CrestorRosuvastatin Calcium20$9,682

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$69,014$276,447206 claims
PfizerEliquis$32$231,844187 claims
NovartisEntresto$584$60,57655 claims
Sanofi-aventis U.S. LLCMultaq$15$57,63233 claims
Arbor Pharmaceuticals, Inc.Edarbi$49$11,49917 claims
AstraZenecaCrestor$125$9,68220 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in East Brunswick

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →